

IFW

Attorney Docket No. RDYN.MRS.18/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	BERGE ET AL.	}	EXAMINER:
SERIAL NO.:	10/789,811		ART UNIT:
FILED:	FEBRUARY 27, 2004		CONFIRMATION NO.:
TITLE:	SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY		

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an

37 CFR 1.8
CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10/15/04
Signature: Tasha L. Pierce
Name: Tasha L. Pierce

admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date:

October 15, 2004

Darla G. Yoerg

Darla G. Yoerg, #48,053

Swanson & Bratschun, L.L.C.

1745 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129

Telephone: (303) 268-0066

Facsimile: (303) 268-0065

S:\CLIENT\FOLDERS\REPLIDYNE\MRS18\UTILITY\IDS.DOC

FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT
AND TRADEMARK
OFFICE

ATTY. DOCKET NO.
RDYN.MRS.18/US


SERIAL NO.
10/789,811

APPLICANT
BERGE ET AL.

FILING DATE
2/27/04

GROUP

List of Information Cited by Applicant
Page 1 of 1



U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	6,320,051	11/20/01	Berge et. al.			
	AB						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AC	EP 0 785 268	7/23/97	EPO			
	AD	WO 00/71522	11/30/00	PCT			
	AE	WO 00/71524	11/30/00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AF	Fleischmann et al. (1995) Science 269:496-512
	AG	Gutschow (1996) J. Het. Chem. 33:355-360
	AI	Lespagnol et al. (1968) Ann Pharm Fr. 26(3):207-14 (and abstract in English)
	AJ	Jarvest et al. (2002) J. Med. Chem. 45:1959
	AK	
	AL	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and <u>not</u> considered. Include copy of this form with next communication to applicant.		

S:\Client\Folders\Replidyne\MRS18\Utility\IDS.doc